Iron and liver cancer

Alcohol

Volumn 30, Issue 2, 2003, Pages 145-150

  Deugnier, Yves ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Hemochromatosis; HFE mutations; Iron; Liver cancer; Oxidative stress

Indexed keywords

ALCOHOL; IRON;

AGING; ALCOHOL CONSUMPTION; CARCINOGENESIS; CHEMICAL MODIFICATION; CONFERENCE PAPER; DISEASE ASSOCIATION; FACILITATION; HUMAN; IMMUNE SYSTEM; LIVER CARCINOMA; OXIDATIVE STRESS; TUMOR GROWTH;

EID: 0042885457     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-8329(03)00129-0     Document Type: Conference Paper

References (67)

1. Aruoma O., Bomford A., Polson R.J., Halliwell B. Nontransferrin-bound iron in plasma from haemochromatosis patients: effect of phlebotomy therapy. Blood. 72:1988;1416-1419.
2. Blanc J.F., De Ledinghen V., Bernard P.H., de Verneuil H., Winnock M., Le Bail B., Carles J., Saric J., Balabaud C., Bioulac-Sage P. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol. 32:2000;805-811.
3. Blumberg R.S., Chopra S., Ibrahim R., Crawford J., Farraye F.A., Zeldis J.B., Berman M.D. Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology. 95:1988;1399-1402.
4. Bradbear R.A., Bain C., Siskind V., Schofield F.D., Webb S., Axelsen E.M., Halliday J.W., Bassett M.L., Powell L.W. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst. 75:1985;81-84.
5. Bralet M., Degott C., Belghiti J., Terris B. Prevalence of the haemochromatosis gene mutation in non-cirrhotic liver with hepatocellular carcinoma. J Hepatol. 28:1998;740.
6. Breimer L.H. Repair of DNA damage induced by reactive oxygen species. Free Radic Res Commun. 14:1991;159-171.
7. Britto M.R., Thomas L.A., Balaratnam N., Griffiths A.P., Duane P.D. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand J Gastroenterol. 35:2000;889-893.
8. Carthew P., Edwards R.E., Smith A.G., Dorman B., Francis J.E. Rapid induction of hepatic fibrosis in the gerbil after parenteral administration of iron-dextran complex. Hepatology. 13:1991;534-539.
9. Chenoufi N., Loréal O., Drénou B., Cariou S., Hubert N., Leroyer P., Brissot P., Lescoat G. Iron may induce both DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J Hepatol. 26:1997;650-658.
10. de Souza M., Porto G., Arosa F., Cardoso C., Cabeda J., LaCerda R., Fraga R. T-lymphocyte expression and function in hemochromatosis. Barton J., Edwards C. Hemochromatosis. 2000;396-407 Cambridge University Press, Cambridge.
11. Deugnier Y., Loréal O. Iron as a carcinogen. Barton J., Edwards C. Hemochromatosis. 2000;239-249 Cambridge University Press, Cambridge.
12. Deugnier Y., Loréal O., Turlin B., Guyader D., Jouanolle H., Moirand R., Jacquelinet C., Brissot P. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology. 102:1992;2050-2059.
13. Deugnier Y.M., Charalambous P., Le Quilleuc D., Turlin B., Searle J., Brissot P., Powell L.W., Halliday J.W. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology. 18:1993a;1363-1369.
14. Deugnier Y.M., Guyader D., Crantock L., Lopez J.M., Turlin B., Yaouanq J., Jouanolle H., Campion J.P., Launois B., Halliday J.W., Powell L., Brissot P. Primary liver cancer in genetic hemochromatosis: a clinical, pathological and pathogenetic study of 54 cases. Gastroenterology. 104:1993b;228-234.
15. Djeha A., Brock J.H. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol. 80:1992;235-241.
16. Fargion S., Fracanzani A.L., Piperno A., Braga M., D'Alba R., Ronchi G., Fiorelli G. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology. 20:1994;1426-1431.
17. Fargion S., Mandelli C., Piperno A., Cesana B., Fracanzani A.L., Fraquelli M., Bianchi P.A., Fiorelli G., Conte D. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 15:1992;655-659.
18. Fellows I.W., Stewart M., Jeffcoate W.J., Smith P.G., Toghill P.J. Hepatocellular carcinoma in primary haemochromatosis in the absence of cirrhosis. Gut. 29:1988;1603-1606.
19. Fracanzani A.L., Conte D., Fraquelli M., Taioli E., Mattioli M., Losco A., Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 33:2001a;647-651.
20. Fracanzani A.L., Taioli E., Sampietro M., Fatta E., Bertelli C., Fiorelli G., Fargion S. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 35:2001b;498-503.
21. Ganne-Carrie N., Christidis C., Chastang C., Ziol M., Chapel F., Imbert-Bismut F., Trinchet J.C., Guettier C., Beaugrand M. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis - a prospective follow up study. Gut. 46:2000;277-282.
22. Glei M., Latunde-Dada G.O., Klinder A., Becker T.W., Hermann U., Voigt K., Pool-Zobel B.L. Iron-overload induces oxidative DNA damage in the human colon carcinoma cell line HT29 clone 19A. Mutat Res. 519:2002;151-161.
23. Goh J., Callagy G., McEntee G., O'Keane J.C., Bomford A., Crowe J. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. Eur J Gastroenterol Hepatol. 11:1999;915-919.
24. Gonzales J., Benirchke K., Saltman P., Roberts J., Robinson P. Hemosiderosis in lemurs. Zoo Biol. 3:1984;255-265.
25. Grando-Lemaire V., Guettier C., Chevret S., Beaugrand M., Trinchet J.C. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol. 31:1999;508-513.
26. Green R., Esparza I., Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci. 526:1988;301-309.
27. Halliday J.W., Searle J. Hepatic iron deposition in human disease and animal models. Biometals. 9:1996;205-209.
28. Hann H.W., Stahlhut M.W., Hann C.L. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 11:1990;566-569.
29. Hann H.W.L., Kim C.Y., London W.T., Blumberg B.S. Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma. Int J Cancer. 43:1989;376-379.
30. Harada T., Baba M., Torii I., Morikawa S. Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. Cell Immunol. 109:1987;75-88.
31. 1 in genetic hemochromatosis. Hepatology. 26:1997;605-610.
32. Hussain S.P., Raja K., Amstad P.A., Sawyer M., Trudel L.J., Wogan G.N., Hofseth L.J., Shields P.G., Billiar T.R., Trautwein C., Höhler T., Galle P.R., Phillips D.H., Markin R., Marrogi A.J., Harris C.C. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci U S A. 97:2000;12770-12775.
33. Kato J., Kobune M., Kohgo Y., Sugawara N., Hisai H., Nakamura T., Sakamaki S., Sawada N., Niitsu Y. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats. J Clin Invest. 98:1996;923-929.
34. Le N.T., Richardson D.R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 1603:2002;31-46.
35. Lemmer E.R., Gelderblom W.C., Shephard E.G., Abel S., Seymour B.L., Cruse J.P., Kirsch R.E., Marasas W.F., Hall P.M. The effects of dietary iron overload on fumonisin B1-induced cancer promotion in the rat liver. Cancer Lett. 146:1999;207-215.
36. Linet M.S., Gridley G., Nyren O., Mellemkjaer L., Olsen J.H., Keehn S., Adami H.O., Fraumeni J.F. Jr. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol. 149:1999;1010-1015.
37. Loeb L.A., James E.A., Waltersdorph A.M., Klebanoff S.J. Mutagenesis by the autoxydation of iron with isolated DNA. Proc Natl Acad Sci U S A. 85:1988;3918-3922.
38. Loréal O., Gosriwatana I., Guyader D., Porter J., Brissot P., Hider R.C. Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol. 32:2000;727-733.
39. Madra S., Styles J., Smith A.G. Perturbation of hepatocyte nuclear populations induced by iron and polychlorinated biphenyls in C57BL/10ScSn mice during carcinogenesis. Carcinogenesis. 16:1995;719-727.
40. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., Le Gall J.Y., Brissot P., David V., Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology. 117:1999;1155-1163.
41. Merk K., Mattsson B., Mattsson A., Holm G., Gullbring B., Björkholm M. The incidence of cancer among blood donors. Int J Epidemiol. 19:1990;505-509.
42. Moirand R., Guyader D., Mendler M.H., Jouanolle A.M., Le Gall J.Y., David V., Brissot P., Deugnier Y. HFE based re-evaluation of heterozygous hemochromatosis. Am J Med Genet. 111:2002;356-361.
43. Moirand R., Mortaji A., Loréal O., Paillard F., Brissot P., Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 349:1997;95-97.
44. Nelson R.L., Davis F.G., Persky V., Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer. 76:1995;875-879.
45. Niederau C., Fischer R., Pürschel A., Stremmel W., Häussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 110:1996;1107-1119.
46. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med. 313:1985;1256-1262.
47. Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int. 46:1996;311-332.
48. Pietrangelo A., Rocchi E., Schiaffonati L., Ventura E., Cairo G. Liver gene expression during chronic dietary iron overload in rats. Hepatology. 11:1990;798-804.
49. Pigeon C., Turlin B., Iancu T.C., Leroyer P., Le Lan J., Deugnier Y., Brissot P., Loréal O. Carbonyl-iron supplementation induces hepatocyte nuclear changes in BALB/CJ male mice. J Hepatol. 30:1999;926-934.
50. Pirisi M., Toniutto P., Uzzau A., Fabris C., Avellini C., Scott C., Apollonio L., Beltrami C.A., Bresadola F. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer. 89:2000;297-302.
51. Randell M.G., Patnaik A.K., Gould W.J. Hepatopathy associated with excessive iron storage in Mynah birds. J Am Vet Med Assoc. 179:1981;1214-1217.
52. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 349:1997;321-323.
53. 2 Knockout mice develop parenchymal iron overload: a putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci U S A. 93:1996;1529-1534.
54. Salata H., Cortès J.M., Enriquez de Salamanca R., Oliva H., Castro A., Kusak E., Carreno V., Hernandez Guio C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol. 1:1985;477-487.
55. Seligman P.A., Klausner R.D., Huebers H.A. Molecular mechanisms of iron metabolism. Neinhuis A., Majerus G., Stamatoyannopoulos G., Leder P. Molecular Basis of Blood Disease. 1987;219 Saunders, Philadelphia.
56. Smith A.G., Carthew P., Francis J.E., Cabral J.R., Manson M.M. Enhancement by iron of hepatic neoplasia in rats caused by hexachlorobenzene. Carcinogenesis. 14:1993;1381-1387.
57. Smith P.G., Yeoh G.C.T. Chronic iron overload in rats induces oval cells in the liver. Am J Pathol. 149:1996;389-398.
58. Stål P., Hultcrantz R., Moller L., Eriksson L.C. The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology. 21:1995;521-528.
59. Terada T., Kadoya M., Nakanuma Y., Matsui O. Iron-accumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer. 65:1990;1994-2000.
60. Terada T., Nakanuma Y. Survey of iron-accumulative macroregenerative nodules in cirrhotic livers. Hepatology. 10:1989;851-854.
61. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med. 20:1996;553-566.
62. Toyokuni S., Mori T., Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer. 57:1994;123-128.
63. Turlin B., Juguet F., Moirand R., Le Quilleuc D., Loréal O., Campion J.P., Launois B., Ramée M.P., Brissot P., Deugnier Y. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology. 22:1995;446-450.
64. Vautier G., Bomford A.B., Portmann B.C., Metivier E., Williams R., Ryder S.D. p53 mutations in british patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology. 117:1999;154-160.
65. Williams G.M., Yamamoto R.S. Absence of stainable iron from pre-neoplastic and neoplastic lesions in rat liver with 8-hydroxyquinoline-induced siderosis. J Natl Cancer Inst. 49:1972;685-692.
66. Young I.S., Trouton T.G., Torney J.J., McMaster D., Callender M.E., Trimble E.R. Antioxydant status and lipid peroxidation in hereditary haemochromatosis. Free Radic Biol Med. 16:1994;393-397.
67. Zhou X.D., DeTolla L., Custer R.P., London W.T. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer. 59:1987;1430-1437.